NASDAQ:MTEM Molecular Templates (MTEM) Stock Price, News & Analysis $0.37 -0.02 (-4.64%) (As of 12:56 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends About Molecular Templates Stock (NASDAQ:MTEM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Molecular Templates alerts:Sign Up Key Stats Today's Range$0.36▼$0.4050-Day Range$0.32▼$1.4852-Week Range$0.30▼$5.37Volume465,075 shsAverage Volume2.81 million shsMarket Capitalization$2.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Read More… I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Molecular Templates Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks45th Percentile Overall ScoreMTEM MarketRank™: Molecular Templates scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Molecular Templates. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Templates is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Templates is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Templates has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.97% of the float of Molecular Templates has been sold short.Short Interest Ratio / Days to CoverMolecular Templates has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Molecular Templates has recently increased by 7.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMolecular Templates does not currently pay a dividend.Dividend GrowthMolecular Templates does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.93 Percentage of Shares Shorted4.97% of the float of Molecular Templates has been sold short.Short Interest Ratio / Days to CoverMolecular Templates has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Molecular Templates has recently increased by 7.44%, indicating that investor sentiment is decreasing significantly. News and Social Media1.6 / 5News Sentiment-0.08 News SentimentMolecular Templates has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Molecular Templates this week, compared to 0 articles on an average week.Search Interest7 people have searched for MTEM on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Molecular Templates insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $844,681.00 in company stock.Percentage Held by Insiders13.90% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Molecular Templates' insider trading history. Receive MTEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter. Email Address MTEM Stock News HeadlinesTarget N. V. Biotech Sells 1,279,820 Shares of Molecular Templates, Inc. (NASDAQ:MTEM) StockNovember 19 at 4:38 AM | insidertrades.comWhy Molecular Templates (MTEM) Stock Is Down 77% TodayOctober 14, 2024 | benzinga.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… November 21, 2024 | Crypto 101 Media (Ad)Molecular Templates Approves Liquidation, Wind Up of CompanyOctober 11, 2024 | marketwatch.comStocks to Watch: Boeing, Vera Bradley, Molecular TemplatesOctober 11, 2024 | marketwatch.comMolecular Templates (NASDAQ:MTEM) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comTemplate synthesis creates multilayered perovskites with unique ferroelectric behaviorSeptember 18, 2024 | msn.comMolecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate UpdateAugust 14, 2024 | globenewswire.comSee More Headlines MTEM Stock Analysis - Frequently Asked Questions How have MTEM shares performed this year? Molecular Templates' stock was trading at $3.73 at the beginning of 2024. Since then, MTEM shares have decreased by 90.1% and is now trading at $0.3681. View the best growth stocks for 2024 here. How were Molecular Templates' earnings last quarter? Molecular Templates, Inc. (NASDAQ:MTEM) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) EPS for the quarter, missing analysts' consensus estimates of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to analyst estimates of $15.69 million. Molecular Templates had a negative net margin of 61.35% and a negative trailing twelve-month return on equity of 260.50%. When did Molecular Templates' stock split? Molecular Templates's stock reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Molecular Templates? Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Molecular Templates own? Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings11/15/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MTEM CUSIP88580720 CIK1183765 Webwww.mtem.com Phone(512) 869-1555Fax650-474-2529Employees62Year Founded2009Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,120,000.00 Net Margins-61.35% Pretax Margin-61.39% Return on Equity-260.50% Return on Assets-46.90% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual Sales$23.48 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book0.50Miscellaneous Outstanding Shares6,584,000Free Float5,669,000Market Cap$2.55 million OptionableNo Data Beta1.22 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:MTEM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Templates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.